Lasvic (trade name Lasquufloxacin) is a fluoroquinolone antibiotic used to treat bacterial infections. Since 2019, the drug has been approved in Japan for the treatment of community-acquired pneumonia, respiratory tract infections, and otorhinolaryngological conditions.

The main indications for use include infections caused by sensitive bacterial strains such as streptococci, staphylococci, and Escherichia coli.

The standard adult dosage is one 75 mg tablet once daily, taken orally. In case of renal insufficiency, the dosage may be adjusted.

Possible side effects: gastrointestinal disorders, dizziness and allergic reactions.